PL2855513T3 - Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie - Google Patents

Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie

Info

Publication number
PL2855513T3
PL2855513T3 PL13728288T PL13728288T PL2855513T3 PL 2855513 T3 PL2855513 T3 PL 2855513T3 PL 13728288 T PL13728288 T PL 13728288T PL 13728288 T PL13728288 T PL 13728288T PL 2855513 T3 PL2855513 T3 PL 2855513T3
Authority
PL
Poland
Prior art keywords
sbv
vaccine
production
methods
schmallenberg virus
Prior art date
Application number
PL13728288T
Other languages
English (en)
Polish (pl)
Inventor
Veljko Nikolin
Konrad Stadler
Axel Lischewski
Alexander Brix
Jeffrey P. Knittel
Katharina Hedwig Toepfer
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PL2855513T3 publication Critical patent/PL2855513T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12061—Methods of inactivation or attenuation
    • C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13728288T 2012-06-01 2013-05-29 Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie PL2855513T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170631 2012-06-01
EP13157875 2013-03-05
EP13728288.5A EP2855513B1 (en) 2012-06-01 2013-05-29 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof

Publications (1)

Publication Number Publication Date
PL2855513T3 true PL2855513T3 (pl) 2017-05-31

Family

ID=48607368

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13728288T PL2855513T3 (pl) 2012-06-01 2013-05-29 Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie

Country Status (17)

Country Link
US (2) US9370562B2 (enExample)
EP (1) EP2855513B1 (enExample)
JP (1) JP6250649B2 (enExample)
CN (1) CN104350066B (enExample)
AR (1) AR091240A1 (enExample)
AU (1) AU2013267453C1 (enExample)
BR (1) BR112014029515A2 (enExample)
CA (1) CA2872961A1 (enExample)
DK (1) DK2855513T3 (enExample)
EA (1) EA034543B1 (enExample)
ES (1) ES2617351T3 (enExample)
IN (1) IN2014DN08927A (enExample)
MX (1) MX363044B (enExample)
PL (1) PL2855513T3 (enExample)
SG (1) SG11201407619SA (enExample)
UY (1) UY34840A (enExample)
WO (1) WO2013181270A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6250649B2 (ja) 2012-06-01 2017-12-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用
EP2855512B1 (en) 2012-06-01 2018-02-28 Boehringer Ingelheim Vetmedica GmbH Genomic sequences of schmallenberg virus and uses thereof
HK1216006A1 (zh) * 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
CN104232587B (zh) * 2014-09-02 2016-08-17 中国检验检疫科学研究院 稳定表达施马伦贝格病毒核衣壳蛋白的细胞系及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811736B2 (ja) * 1986-08-07 1996-02-07 財団法人化学及血清療法研究所 牛流行熱・イバラキ病・アカバネ病３種混合不活化ワクチン
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US20080226682A1 (en) * 2007-03-13 2008-09-18 Peros Systems Technologies, Inc. Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
JP6250649B2 (ja) 2012-06-01 2017-12-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ シュマレンベルクウイルス（ｓｂｖ）ワクチン、その製造方法及び使用
EP2855512B1 (en) 2012-06-01 2018-02-28 Boehringer Ingelheim Vetmedica GmbH Genomic sequences of schmallenberg virus and uses thereof

Also Published As

Publication number Publication date
US9872897B2 (en) 2018-01-23
AU2013267453A1 (en) 2014-11-13
EP2855513A1 (en) 2015-04-08
ES2617351T3 (es) 2017-06-16
JP2015519367A (ja) 2015-07-09
JP6250649B2 (ja) 2017-12-20
EA201401352A1 (ru) 2015-05-29
CN104350066A (zh) 2015-02-11
AU2013267453B2 (en) 2017-04-06
US9370562B2 (en) 2016-06-21
UY34840A (es) 2013-12-31
EP2855513B1 (en) 2016-12-07
WO2013181270A1 (en) 2013-12-05
EA034543B1 (ru) 2020-02-19
DK2855513T3 (en) 2017-03-13
US20160250317A1 (en) 2016-09-01
AR091240A1 (es) 2015-01-21
BR112014029515A2 (pt) 2017-07-25
SG11201407619SA (en) 2014-12-30
US20130323277A1 (en) 2013-12-05
IN2014DN08927A (enExample) 2015-05-22
CN104350066B (zh) 2018-06-19
AU2013267453C1 (en) 2017-08-10
MX363044B (es) 2019-03-06
CA2872961A1 (en) 2013-12-05
MX2014014521A (es) 2015-02-24

Similar Documents

Publication Publication Date Title
IL261204A (en) Influenza virus vaccines and their use
IL262123A (en) Influenza virus vaccines and their uses
IL261372A (en) Preparations, uses and solid forms of obeticholic acid
ZA201404797B (en) Influenza virus vaccines and uses thereof
IL229419A0 (en) Heat-stable vaccines and methods for their preparation
PL2882779T3 (pl) Pochodna kwasu hialuronowego, sposób jej wytwarzania, sposób jej modyfikacji i jej zastosowanie
IL269622A (en) Preparation of (S–S)-scoisolaricirsinol diglucoside and (R–R)-scoisolaricisrinol diglucoside
IL240227A0 (en) Immunogenic compositions containing viruses treated with silicates and methods of use
HUE040649T2 (hu) Chidamid kristályformája, eljárás elõállítására és alkalmazása
EP2766375A4 (en) PREPARATION OF NEW FLUORIN COMPOUNDS, METHOD OF MANUFACTURING AND COMPOSITIONS MADE THEREOF
EP2802349A4 (en) IMMUNOGENIC VLP CONTAINING L2 HPV AND COMPOSITIONS AND METHODS THEREOF
ZA201500450B (en) Novel rebamipide prodrugs, preparation method and use thereof
ZA201503410B (en) Method of making alpha, omega-diiodoperfluoroalkanes
ZA201501601B (en) Virus purification and formulation process
PL2855513T3 (pl) Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie
SG11201504500QA (en) Syringe devices, components of syringe devices, and methods of forming components and syringe devices
EP2688576A4 (en) HEAT-EXTRACTED EPIPLOON EXTRACTS, COMPOSITIONS, PREPARATION METHODS AND USES THEREOF
EP2925436A4 (en) METAL PHOSPHATE MOLECULAR SIEBE, METHOD FOR THE PREPARATION AND USE
SG11201500508XA (en) Production of infectious influenza viruses
EP2945703A4 (en) ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
EP2870133A4 (en) TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF
AU2012901774A0 (en) Vaccine and uses thereof
AU2012902151A0 (en) Immunogenic vaccines and uses thereof